The following study has recently been activated for patient enrollment by The University of Illinois Cancer Center Clinical Trials Office (CTO). Clink on the link to learn about the details regarding the study on clinicaltrials.gov.
For more information or questions about a study, email email@example.com or call 312-355-5112.
A081801: Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Sponsor: National Cancer Institute, Alliance
Principal Investigator: Lawrence Feldman, MD